文献速递肝病

肝脏硬度测量作为无创方法诊断慢性丁型肝炎病毒感染患者肝硬化的研究

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection.
PubMed 文献 · Aliment Pharmacol Ther · 2024-01-11

该回顾性多中心队列研究纳入144例慢性丁型肝炎患者,评估瞬时弹性成像肝脏硬度测量(LSM)诊断肝硬化的性能。肝硬化组织学诊断22例(15.3%),LSM诊断肝硬化AUROC为0.89,优于其他无创指标;切点≥15.2 kPa排除肝硬化NPV 98%,切点<10.2 kPa诊断非进展性纤维化正确识别90%患者。结论认为LSM是有用工具但不能完全替代肝活检。

要点

  • LSM诊断肝硬化AUROC 0.89,优于D4FS、APRI、FIB-4和AAR。
  • 切点≥15.2 kPa诊断肝硬化Se 91%、Sp 84%、PPV 50%、NPV 98%。
  • 切点<10.2 kPa诊断非进展性纤维化(Metavir ≤2)正确识别90%患者。

核心结论

  • LSM是识别慢性丁型肝炎患者肝硬化风险的有用工具,优于其他无创指标。
  • 切点<10.2和<15.2 kPa可可靠诊断非进展性肝纤维化并在多数患者中排除肝硬化。
  • LSM不能完全替代慢性丁型肝炎患者的肝活检。

研究设计与样本

  • 回顾性多中心队列研究,纳入144例慢性丁型肝炎患者,均有配对(±6个月)的LSM和肝活检。
  • 数据在132例慢性丁型肝炎患者的独立队列中验证。

主要发现

  • 肝硬化组织学诊断22例(15.3%)。
  • 肝硬化患者平均LSM 23.4 kPa,显著高于无纤维化患者的10.2 kPa(p < 0.0001)。
  • 肝硬化患者平均LSM 23.4 kPa,显著高于中间纤维化患者的13.5 kPa(p < 0.0001)。
  • 诊断肝硬化AUROC:LSM 0.89、D4FS 0.87、APRI 0.74、FIB-4 0.73、AAR 0.69。

关键数值与推荐

  • 识别肝硬化最佳切点≥15.2 kPa(Se 91%、Sp 84%、PPV 50%、NPV 98%)。
  • 诊断非进展性肝纤维化(Metavir ≤2)理想切点<10.2 kPa(Se 55%、Sp 86%、PPV 90%、NPV 45%),正确识别90%患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Noninvasive tests (NITs) have been proposed as an alternative to liver biopsy for diagnosing liver cirrhosis. The evidence of NIT performance in patients with chronic hepatitis D (CHD) is limited. AIMS: To evaluate the diagnostic performance of liver stiffness measurement (LSM) and other NITs in CHD patients. METHODS: We evaluated the diagnostic performance of LSM by transient elastography for the detection of liver cirrhosis in a retrospective, multicentre cohort of 144 CHD patients with paired (±6 months) LSM and liver biopsies. RESULTS: Cirrhosis was diagnosed histologically in 22 patients (15.3%). Mean LSM was significantly higher in patients with cirrhosis compared to those without fibrosis (23.4 vs 10.2 kPa, p < 0.0001) or with intermediate fibrosis (23.4 vs 13.5 kPa, p < 0.0001). In the detection of liver cirrhosis, LSM was superior to other NITs (AUROCs: 0.89 [LSM], 0.87 [D4FS], 0.74 [APRI], 0.73 [FIB-4], and 0.69 [AAR]). The optimal cut-off for identifying patients with liver cirrhosis was ≥15.2 kPa (Se 91%, Sp 84%, PPV 50%, NPV 98%). The ideal cut-off for diagnosing non-advanced liver fibrosis (Metavir ≤2) was <10.2 kPa (Se 55%, Sp 86%, PPV 90%, NPV 45%), correctly identifying 90% of patients. Data were validated in an independent cohort of 132 CHD patients. CONCLUSIONS: LSM is a useful tool for identifying patients at risk for liver cirrhosis and is superior to other NITs. The cut-offs of <10.2 and < 15.2 kPa reliably diagnose non-advanced liver fibrosis and exclude cirrhosis in the majority of patients. However, LSM cannot completely replace liver biopsy in CHD patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sandmann L, Degasperi E, Port K, et al. Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection. Aliment Pharmacol Ther. 2024. PMID: 38212890. doi:10.1111/apt.17878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。